Evaluation of in-vitro antiviral potential of Psidium guajava L. Extract against influenza A/(H1N1)pdm09 virus.

The rise of drug-resistant Influenza strains necessitates the development of new antiviral therapies. This study investigated the antiviral potential of aqueous extracts of Psidium guajava L. against the Influenza A/(H1N1)pdm09 virus. The extracts demonstrated significant antiviral activity and therapeutic efficacy in-vitro, achieving 99.98% virus suppression in co-treatment. FTIR analysis confirmed the presence of bioactive compounds such as phenolics, terpenoids, and alkaloids. Additionally, the extracts exhibited potent antioxidant activity, further enhancing their therapeutic potential. The efficacy of the extracts varied depending on the timing of treatment, with co-treatment yielding the best results, followed by some effectiveness in post-treatment scenario. Cytotoxicity assays confirmed the safety of Psidium guajava extracts on MDCK cells at therapeutic concentrations (CC₅₀ > 100 µg/mL). These findings suggest that Psidium guajava extracts hold promise as potential candidates for the development of anti-influenza medications, particularly due to their multi-target efficacy.